Cleveland, Jul 10 (AP/UNB) — The Cleveland Clinic says it has delivered the first baby in North America after a womb transplant from a dead donor.
Uterine transplants have enabled more than a dozen women to give birth, usually with wombs donated from a living donor such as a friend or relative. In December, doctors in Brazil reported the world's first birth using a deceased donor's womb.
These transplants were pioneered by a Swedish doctor who did the first successful one five years ago.
The Cleveland hospital said Tuesday that the girl was born in June. The clinic has done five uterus transplants so far and three have been successful, with two women waiting to attempt pregnancy with new wombs. In all, the clinic aims to enroll 10 women in its study.
Westland, Jul 10 (AP/UNB) — An annual clash between good, clean fun and down-and-dirty theatrics has once again left scores of mud-covered children smiling in a suburban Detroit park.
Children participated in the 32nd annual Wayne County Mud Day on Tuesday at Nankin Mills Park in Westland, a suburb west of Detroit. Participants frolicked, bathed and lounged in a large mud pit, then sloppily engaged in Mud Limbo and Wheelbarrow Races.
There also was majesty amid the muck and mud: Phoenix Crowder and Riley Tulgetske were crowned Mud Day King and Queen.
A local fire department rig sprayed water to rinse off the mud-caked revelers — to the chagrin of some mud enthusiasts.
Dhaka, Jul 8 (UNB) - A strain of the common cold virus can infect and kill bladder cancer cells, a small study suggests, reports the BBC.
All signs of the disease disappeared in one patient, and in 14 others there was evidence that cancer cells had died.
University of Surrey researchers said the virus could "help revolutionise treatment" for the cancer and reduce the risk of it recurring.
A bladder cancer charity called the study "very exciting" if larger studies confirmed the findings.
Non-muscle invasive bladder is the 10th most common cancer in the UK, with around 10,000 new cases each year.
Current treatments for this type of bladder cancer are invasive or can cause serious, toxic side effects.
And constant, costly monitoring is needed to check that the cancer has not returned after treatment.
'Join the party'
In this study, 15 patients with the disease were given the cancer-killing coxsackievirus (CVA21) through a catheter one week before surgery to remove their tumours.
When tissues samples were analysed after surgery, there were signs the virus had targeted and killed cancer cells in the bladder.
Once these cells had died, the virus had then reproduced and infected other cancerous cells - but all other healthy cells were left intact.
What the virus does is special, says study leader Prof Hardev Pandha, from the University of Surrey and Royal Surrey County Hospital.
"The virus gets inside cancer cells and kills them by triggering an immune protein - and that leads to signalling of other immune cells to come and join the party," he said.
Normally, the tumours in the bladder are "cold" because they do not have immune cells to fight off the cancer.
But the actions of the virus turn them "hot", making the body's immune system react.
Prof Pandha said the same virus had also been tested on skin cancer, but this was the first time it had been studied in a clinical trial on bladder cancer.
"Reduction of tumour burden and increased cancer cell death was observed in all patients, and removed all trace of the disease in one patient following just one week of treatment, showing its potential effectiveness," he said.
"Notably, no significant side effects were observed in any patient."
'New era in treatment'
The plan is now to use the common cold virus with a targeted immunotherapy drug treatment, called a checkpoint inhibitor, in a future trial in more patients.
Dr Nicola Annels, research fellow at the University of Surrey, said viruses like the coxsackievirus "could signal a move away from more established treatments such as chemotherapy".
Allen Knight, chairman of Action Bladder Cancer UK, said the study findings were "very exciting".
Bladder cancer costs the NHS more per patient than nearly every other cancer, because of the high recurrence rate, he said.
"If the safety, tolerability, and efficacy data can be confirmed in larger clinical studies and trials, then it could herald a new era in the treatment for non-muscle-invasive bladder cancer patients, like me, who often feel that innovations in cancer therapies pass us by."
Dr Mark Linch, a bladder cancer expert at the Cancer Research UK Cancer Institute at University College London, said the initial results were "encouraging".
"It will be really interesting to see how this new virus-based therapy fares in larger trials in people with non-muscle invasive bladder cancer, particularly in combination with newer immunotherapies," he said.
Chicago, Jul 8 (AP/UNB) — Alzheimer's disease may be a risk for older prostate cancer patients given hormone-blocking treatment, a large, U.S. government-funded analysis found.
Previous evidence has been mixed on whether the treatment might be linked with mental decline. But experts say the new results stand out because they're from a respected national cancer database and the men were tracked for a long time — eight years on average.
Among 154,000 older patients, 13% who received hormone-blocking treatment developed Alzheimer's, compared with 9% who had other treatment or chose no therapy, the study found.
The risk for dementia from strokes or other causes was higher: It was diagnosed in 22% of those who got hormone-blocking treatment, versus 16% of the other patients.
The results, using perhaps one of the largest and most reliable databases, suggests there truly may be a connection, said Dr. Sumanta Pal, a prostate cancer expert with the American Society of Clinical Oncology. Pal was not involved in the study.
The analysis from University of Pennsylvania researchers was published Friday in JAMA Network Open.
The results aren't proof but experts say they underscore the importance of discussing potential risks and benefits when choosing cancer treatment.
The researchers analyzed data from a National Cancer Institute database of cancer cases and treatment and covers almost 30% of the U.S. population. The study focused on men in their 70s, on average, with local or advanced prostate cancer diagnosed between 1996 and 2003. They were followed until 2013. Medicare records indicated dementia or Alzheimer's diagnosis.
Hormone-blocking treatment can include testes removal to reduce levels of testosterone, which fuels prostate cancer growth. But it more typically involves periodic drug injections or implants that achieve the same result.
Most U.S. men who receive this treatment are in their 70s or older. It's sometimes used in men who might not be healthy enough to tolerate other cancer treatments including surgery to remove the prostate and radiation.
It's unclear how the treatment might be linked with mental decline. The researchers noted that it can lead to diabetes, which also has been linked with dementia — perhaps because blood vessel damage from diabetes can restrict blood flow to the brain. Hormone treatment also raises risks for heart disease and depression, which both have been linked with dementia.
Researcher Grace Lu-Yao of the Sidney Kimmel Cancer Center in Philadelphia, said the potential dementia risks from hormone-blocking treatment may outweigh any benefit for younger, healthier patients with longer expected life spans.
While the study doesn't prove that the treatment causes dementia, she said, it is important to tell patients "because of the potential impact of Alzheimer's disease or dementia on the quality of life of patients and their family." She was not involved in the study.
Dhaka, July 8 (UNB) - Losing just 16 minutes of sleep could be the difference between a clear-headed day at the office or one filled with distractions, say scientists, reports The IndianExpress.
A study, published in the journal Sleep Health, found that reducing your sleep routine during the work-week greatly interferes with job performance.
The researchers from University of South Florida in the US found workers are more likely to have poor judgement and fall off-task the next day.
Researchers surveyed 130 healthy employees who work in Information Technology and have at least one school-aged child.
Participants reported that when they slept 16 minutes less than usual and had worse quality sleep, they experienced more cognitive issues the next day.
That raised their stress levels, especially regarding issues related to work-life balance, resulting in them going to bed earlier and waking up earlier due to fatigue.
“These cyclical associations reflect that employees’ sleep is vulnerable to daily cognitive stress and also a contributor to cognitively stressful experiences,” said Soomi Lee, assistant professor at University of South Florida.
“Findings from this study provide empirical evidence for why workplaces need to make more efforts to promote their employees’ sleep. Good sleepers may be better performers at work due to greater ability to stay focused an on-task with fewer errors and interpersonal conflicts,” said Lee.
Researchers also compared work-days to weekends. They conclude the consequences of less sleep is not as apparent when one has the next day off from work.